Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations

Solid Biosciences Inc.

Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.
Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.
Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.
Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.